Olaru Ioana D, Beliz Meier Mina, Mirzayev Fuad, Prodanovic Nevena, Kitchen Philip J, Schumacher Samuel G, Denkinger Claudia M
Division of Infectious Disease and Tropical Medicine, Heidelberg University Hospital, 324 Im Neuenheimer Feld, 69120, Heidelberg, Germany.
Clinical Research Department, London School of Hygiene and Tropical Medicine, Keppel Street, WC1E 7HT, London, United Kingdom.
EClinicalMedicine. 2023 Apr 6;58:101938. doi: 10.1016/j.eclinm.2023.101938. eCollection 2023 Apr.
There is a substantial overlap in the epidemiology of chronic hepatitis B (HBV), hepatitis C (HCV) and tuberculosis (TB) due to overlapping risk factors. Testing for viral hepatitis is not widely recommended for patients with TB. The aim of this systematic review was to evaluate the global prevalence of chronic viral hepatitis infection among patients with TB.
MEDLINE, EMBASE, Web of Science, Cochrane Library, African Journals Online, LILACS, and country TB reports were searched for studies published between January 1st, 2011 and June 17th 2021. Random-effects meta-analyses for proportions were conducted to obtain pooled prevalences. The prevalence of chronic HBV/HCV infection among patients with TB was also compared to that in the general population. The protocol was registered on PROSPERO (CRD42021276468).
This analysis included 127 studies (83 for both HBV and HCV, 28 for HBV only, and 25 for HCV only) and data from 94,936 patients. The global pooled seroprevalence was 5.8% (95% CI 5.0-6.8) for HBs-antigen and 10.3% (95% CI 8.4-12.3) for HCV-antibodies. Pooled prevalence was highest in the WHO African Region for HBV at 7.8% (95% CI 5.2-10.9) and in the WHO European Region at 17.5% (95% CI 12.2-23.5) for HCV. In studies among TB patients who inject drugs, HCV prevalence was 92.5% (95% CI 80.8-99.0). Pooled HCV-antibody seroprevalence among patients with TB was higher than in the general population in all six WHO regions while HBs-antigen seroprevalence was higher in 3/6 regions.
This review highlights the syndemicity of chronic viral hepatitis and TB and suggests that routine testing for hepatitis upon TB diagnosis may be justified. The prevalence of chronic HBV and HCV infections was higher among patients with TB than in the general population.
This study was study was funded by the Global Tuberculosis Programme, World Health Organization.
由于风险因素重叠,慢性乙型肝炎(HBV)、丙型肝炎(HCV)和结核病(TB)的流行病学存在大量重叠。对于结核病患者,病毒型肝炎检测并未得到广泛推荐。本系统评价的目的是评估结核病患者中慢性病毒型肝炎感染的全球患病率。
检索MEDLINE、EMBASE、科学网、考克兰图书馆、非洲期刊在线、拉丁美洲及加勒比卫生科学数据库以及各国结核病报告,查找2011年1月1日至2021年6月17日期间发表的研究。进行随机效应荟萃分析以获得合并患病率。还比较了结核病患者中慢性HBV/HCV感染的患病率与普通人群中的患病率。该方案已在国际前瞻性系统评价注册库(PROSPERO)注册(注册号:CRD42021276468)。
该分析纳入了127项研究(83项同时涉及HBV和HCV,28项仅涉及HBV,25项仅涉及HCV)以及来自94,936名患者的数据。HBs抗原的全球合并血清阳性率为5.8%(95%置信区间5.0 - 6.8),HCV抗体的全球合并血清阳性率为10.3%(95%置信区间8.4 - 12.3)。HBV合并患病率在世界卫生组织非洲区域最高,为7.8%(95%置信区间5.2 - 10.9);HCV合并患病率在世界卫生组织欧洲区域最高,为17.5%(95%置信区间12.2 - 23.5)。在注射毒品的结核病患者中,HCV患病率为92.5%(95%置信区间80.8 - 99.0)。在世界卫生组织的所有六个区域中,结核病患者中HCV抗体合并血清阳性率均高于普通人群,而HBs抗原血清阳性率在3/6个区域中更高。
本评价突出了慢性病毒型肝炎和结核病的共病现象,并表明在结核病诊断时对肝炎进行常规检测可能是合理的。结核病患者中慢性HBV和HCV感染的患病率高于普通人群。
本研究由世界卫生组织全球结核病规划资助。